Earlier we implicated nitric oxide (NO) in mediation of the behavioral effects of benzodiazepines. Since benzodiazepines work through facilitation of GABAergic inhibitory neurotransmission, this study was designed to determine whether the direct-acting g-aminobutyric acid A (GABA A ) receptor agonist THIP (4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol) evokes behavioral effects similar to those of benzodiazepines and whether behavioral effects of THIP are also NO dependent. When challenged with either chlordiazepoxide or THIP in an elevated plus-maze paradigm, male NIH Swiss mice exhibited a dose-related increase in open-arm activity. The chlordiazepoxide-induced effects were sensitive to antagonism by a benzodiazepine antagonist, and the effects of THIP were blocked by a GABA A receptor antagonist. Pretreatment with the NO synthase (NOS) inhibitor L-N G -nitro arginine antagonized the effects of both chlordiazepoxide and THIP; similar pretreatment with the D-isomer, D-N G -nitro arginine, which is inactive as an NOS inhibitor, was without effect on chlordiazepoxide and THIP. These findings indicate that chlordiazepoxide and THIP evoke similar behavioral effects in mice in the elevated plus-maze through actions on different parts of the GABA A receptor, and that NO appears to play a key role in mediation of the behavioral effects of both chlordiazepoxide and THIP.
INTRODUCTION
The g-aminobutyric acid A (GABA A ) receptor-chloride channel complex is a heteropentameric protein polymer comprised of homologous membrane-spanning glycoprotein subunits (Sieghart, 1995; Whiting et al, 1995) . Benzodiazepines are positive allosteric modulators of GABAergic neurotransmission. The benzodiazepine binding site is sited in a cleft between the a 1 and g 2 subunits and increases the affinity of chloride channel openings by GABA, which acts at its own distinct receptor site between the a 1 and b 2 subunits (Sigel, 2002) . Thus, activation of the benzodiazepine site causes an increase in GABA inhibition.
A number of studies have established a relationship between activity at the GABA A receptor and regulation of anxiety. When tested in ethological models of experimental anxiety such as the elevated plus-maze, mice treated with direct-acting GABA A agonists like muscimol and baclofen respond with an anxiolytic-like behavior (Corbett et al, 1991; Nastiti et al, 1991) . THIP (4,5,6,7-tetrahydroisoxazolo[5,4-c] pyridin-3-ol) is a potent and efficacious directacting agonist at GABA A receptors. It has been reported to produce anxiolytic effects in man (Krogsgaard-Larsen et al, 1997) . A subsequent clinical study confirmed that THIP significantly reduced anxiety ratings on multiple measures but reported that anxiolytic doses also produced sedation and undesirable side effects (Hoehn-Saric, 1983) . In animal studies, THIP partly reduced the behavioral effects of Rhesus monkeys treated with an anxiogenic b-carboline (Crawley et al, 1985) . THIP also exhibited anxiolytic-like activity in rodents in the social interaction test and elevated plus-maze (Corbett et al, 1991) . THIP also suppressed anxiety in a rodent model of premenstrual anxiety (Gulinello et al, 2003) .
Previously we reported that the anxiolytic-like effects of chlordiazepoxide and nitrous oxide were antagonized by inhibition in production of nitric oxide (NO). If benzodiazepine-induced anxiolytic effects are mediated through the GABA receptor (Korpi et al, 2002) and if such benzodiazepine-induced effects can be blocked by inhibitors of nitric oxide synthase (NOS) (Quock and Nguyen, 1992; Li and Quock, 2001; Li et al, 2003b) , then one would expect that the anxiolytic-like responses to a direct GABA A agonist should also be sensitive to antagonism by NOS inhibitors.
MATERIALS AND METHODS

Animals
Male NIH Swiss mice, 18-25 g, were purchased from Harlan Laboratories (Indianapolis, IN) and used in these experiments, which were reviewed and approved by the Biologic Resource Committee, the institutional animal care and use committee of the University of Illinois College of Medicine at Rockford, and were conducted in accordance with The Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) . Mice were housed five per cage in an ALAAAC-accredited animal facility. Food and water were available ad libitum. The facility was maintained on a 12-h light/dark cycle (lights on 0700-1900) under standard conditions (22711C room temperature, 33% humidity). Mice were kept in the holding room for at least 4 days following arrival in the facility prior to use. Animals were used only once.
Elevated Plus-Maze
The elevated plus-maze was constructed from black Chlordiazepoxide and THIP were freshly prepared in 0.9% physiological saline solution and administered intraperitoneally (i.p.) 30 min prior to testing in the elevated plus-maze. CGS 8216 was suspended in 0.3% Tween 80 (Sigma) in saline and administered subcutaneously (s.c.) 30 min prior to testing. L-NOARG and D-NOARG were similarly dissolved in physiological saline and administered s.c. 30 min prior to testing in the plus-maze. The dose of L-NOARG and D-NOARG was determined in preliminary dose-response experiments. Control animals received appropriate vehicle injections i.p. or s.c. The injection volume of drug challenges and pretreatments was 0.1 ml per 10 g body weight.
SR-95531 was administered by the intracerebroventricular (i.c.v.) route in a dose of 2.0 nmol 30 min prior to testing. The drug was delivered directly into the lateral cerebral ventricle of mice lightly anesthetized with halothane using a modification of the method of Haley and McCormick (1957) . An incision was made in the scalp, and the skin was retracted to expose the calvarium. The injection was made using a 26-gauge microsyringe (Hamilton, Reno, Nevada) at a point on calvarium 2.0 mm lateral and 2.0 mm caudal to bregma to a depth of 2.5 mm from the skull surface. The i.c.v. microinjection technique was verified in preliminary experiments by microinjection of a dye marker and finding stained walls in the ipsilateral ventricular space.
Statistical Analysis of Data
The mean percent entries into open arms was calculated as follows: 
DISCUSSION
THIP, also known as gaboxadol, is a directly acting GABA A receptor agonist (Krogsgaard-Larsen et al, 2002) that has reported to produce anxiolytic drug effects in humans (Krogsgaard-Larsen et al, 1997) . Clinical studies of the effects of THIP on human sleep patterns have led to the recently initiated Phase III clinical trials as a treatment for insomnia (H. Lundbeck A/S, a press release; http:// www.pressi.com/int/release/68357.html; Mathias et al, 2001) . The results of the present study show that increasing doses of THIP caused a dose-related increase in open-arm activity not unlike the effects of chlordiazepoxide. The anxiolytic-like effects of THIP were attenuated by the GABA A receptor antagonist SR-95531 but not the benzodiazepine antagonist CGS-8612. The anxiolytic-like effects of chlordiazepoxide were significantly antagonized by CGS-8216 but not SR-95531. In fact, there seemed to be an enhanced response to chlordiazepoxide in the presence of GABA A receptor blockadeFan explanation of this heightened anxiolytic-like effect of chlordiazepoxide effect is not immediately evident. The behavioral effects of both THIP and chlordiazepoxide were sensitive to antagonism by pretreatment with L-NOARG but not D-NOARG. Since only the L-stereoisomer of NOARG can inhibit NOS enzyme activity, it is concluded that THIP and chlordiazepoxide share a common requirement for NO in the signaling mechanism downstream from the GABA A receptor.
These findings are consistent with other research from our laboratory regarding what appears to be a critical involvement of NO in mediating the anxiolytic-like behavioral effects of benzodiazepines in different animal models of experimental anxiety. In earlier research, the effects of chlordiazepoxide in the mouse elevated plus-maze were markedly antagonized by L-NOARG (N G -L-nitro arginine) inhibition of NOS; this antagonism was stereoselectively reversed by treatment with L-arginine but not D-arginine (Quock and Nguyen, 1992 ). L-NOARG, which preferentially inhibits the neuronal and endothelial forms of NOS (Gross et al, 1990; Klatt et al, 1994) , also blocked the ability of chlordiazepoxide to selectively reduce rearing activity in the mouse staircase test, in which rearing is considered an index of anxiety (Lake and Quock, 2001 ). Moreover, the effects of chlordiazepoxide and nitrous oxideFan anesthetic gas that reduces anxiety through direct or indirect activation of brain benzodiazepine receptors Emmanouil et al, 1994) Fin the light/dark exploration test were also antagonized by the neuronal-selective NOS inhibitors 7-nitroindazole (Li and Quock, 2001 ) and S-methyl-l-thiocitrulline (Li et al, 2003b) as well as an antisense oligodeoxynucleotide directed against neuronal NOS (Li et al, 2003a) . Based on these findings, it was concluded that NO might play a key role in mediating the anxiolytic-like behavioral effects of chlordiazepoxide.
It should also be noted that THIP and chlordiazepoxideinduced anxiolytic effects in the elevated plus-maze were both antagonized by a dose of L-NOARG much lower than that used to inhibit NOS in our earlier investigations. Subcutaneous pretreatment with 10 mg/kg effectively antagonized the anxiolytic-like behaviors induced by chlordiazepoxide (Quock and Nguyen, 1992) and nitrous oxide (Caton et al, 1994) in the mouse elevated plus-maze. Preliminary to the present study, we conducted doseresponse experiments of L-NOARG antagonism of chlordiazepoxide and discovered a threshold dose for antagonism of about 0.4 mg/kg. Accordingly, a dose of 0.45 mg/kg was adopted as the standard antagonist dose of L-NOARG for these experiments.
The scientific literature does contain evidence for interaction between GABA and NO, but the majority of such studies focus on NO modulation of the neuronal release of GABA (Wall, 2003; Li et al, 2004) . However, a recent study demonstrated that activation of GABA A receptors by muscimol or activation of the benzodiazepine binding site by diazepam increases the population of nNOSpositive cells in the frontal and parietal areas of the developing cortex (Mantelas et al, 2003) . In addition, activation of GABA receptors increased the count of brain-derived neurotophic factor (BDNF)-and phosphorylated cAMP-response element binding protein (CREB)-doubly positive cells. The increases in the above multiple immunoreactivities were sensitive to antagonism by nimodipine, which blocks L-type voltage-gated calcium channels. Two possible pathways have been postulated. GABA may directly induce nNOS expression as has been demonstrated in mouse cerebellar granule cell culture (Baader et al, 1997) . Alternatively, stimulation of the GABA A receptor may increase expression of BDNF, which has been shown to upregulate NOS activity (Xiong et al, 1999) . In either event, the induction of nNOS and BDNF expression appears to be mediated by the influx of calcium ions that causes phosporylation (activation) of CREB (Sasaki et al, 2000; Auger et al, 2001; Mantelas et al, 2003) .
An analogous mechanism can be envisioned in brain regions where chlordiazepoxide and THIP appear to work to induce anxiolysis. Activation of GABA A receptors may result in activation of CREB which then directly or indirectly through BDNF induce expression of neuronal NOS. Such a mechanism that couples NOS to the GABA A receptor would explain why the anxiolytic effect of benzodiazepines would be NO dependent. However, there is controversy over the precise role of NO in the regulation of anxiety.
Based on our research, if NO mediates the anxiolytic effect of benzodiazepines and nitrous oxide, inhibition of NOS alone should be anxiogenic. A number of research groups have indeed reported that suppression of NO production can induce anxiogenic-like behavior in a variety of animal models of experimental anxiety Vale et al, 1998; Monzon et al, 2001; Pokk and Vali, 2002; Czech et al, 2003) . That NO is involved in reduction of anxiety is supported by the observation that administration of the NO donor 3-morpholinosyndnonimine (SIN-1) evoked an anxiolytic-like response in mice in the light/dark exploration test (Li and Quock, 2002) . Restraint stress induced an anxiogenic-like response in the elevated plusmaze that was suppressed in a diazepam-like manner by L-arginine and exacerbated by L-NAME (Masood et al, 2003) . Diazepam among several psychotropic drugs increases levels of inducible NOS mRNA in rat brain, suggesting that its effects might be mediated by NO (Suzuki et al, 2002) .
However, there is equally convincing evidence implicating exactly the opposite role of NO in anxiety, that is NO appears to be responsible for anxiogenesis. Systemic treatment with L-NAME, L-NOARG and 7-NI produced anxiolytic-like behavior in rats in the elevated plus-maze (Volke et al, 1995; Faria et al, 1997; de Oliveira et al, 1997; Dunn et al, 1998) . Systemic 7-NI produced anxiolytic-like responses in mice in the light/dark exploration test and elevated plus-maze (Volke et al, 1997) . Microinjection of L-NAME and L-NOARG into the dorsolateral periaqueductal gray induced anxiolytic-like behavior in the rat elevated plus-maze, although higher doses produced anxiogenic-like responses (Guimarães et al, 1994) .
In other research, the neuronal-selective NOS inhibitor 1-(2-trifluoromethylphenyl)-imidazole (TRIM) but not 7-NI produced an anxiolytic-like response in mice in the light/ dark exploration test (Volke et al, 2003) . Transient cerebral ischemia in mice causes anxiogenic-like activity in elevated plus-maze and social interaction test that was suppressed by nonselective L-NAME and I-NOS-selective S-ethylisothiourea (EIT) but not nNOS-selective 7-nitroindazole (Nakashima et al, 2003) . Administration of L-arginine, presumed to increase NO production, abolished the anxiolytic-like response of rats to diazepam in the elevated plus-maze (Volke et al, 1998) . There is also increased expression of neuronal NOS mRNA in stress-related brain regions, suggesting an increase in NO during stress (de Oliveira et al, 2000) .
Why there is such disagreement in the relationship of NO to anxiety is the subject of much speculation and investigation. The differences in reported behavioral effects of NOS inhibitors have been attributed to a number of factors, including drugs, doses, experimental species, routes of administration, and models of experimental anxiety (see discussion by Li et al, 2003b) . A significant finding of the present study is that THIP and chlordiazepoxide-induced anxiolytic-like effects were antagonized by pretreatment with 0.45 mg/kg L-NOARG. This is significant in light of the often high doses of NOS inhibitors used to evoke anxiolyticlike effects or provoke anxiogenic-like effects in other elevated plus-maze studies in mice, for example 20 and 40 mg/kg (Pokk and Vali, 2002) , 20 and 40 mg/kg of L-NAME (Pokk and Vali, 2002) , and 80-120 mg/kg 7-NI (Volke et al, 1997; Pokk and Vali, 2002) . Drug dose may be one contributing factor in the incongruities of experimental findings with NOS inhibitors.
A better explanation for these discrepancies may very well lie in the multitude of functions served by NO in the central nervous system. NO may have biphasic influences (ie both excitatory and inhibitory) based on a complex interaction among glutamatergic, GABAergic, and other (eg opioid) neuronal systems, all of which are modulated by NO (Lovick and Key, 1996; Wang et al, 1997; Hall and Behbehani, 1998; Lin et al, 2000) . This may account for the contradictory results that NO appears to both enhance and suppress not only anxiety but also other functions such as pain (Moore et al, 1993; McDonald et al, 1994) , seizure activity (Buisson et al, 1993; De Sarro et al, 1993) , and neurotoxicity (Contestabile et al, 2003) . These findings are contributing to a more complete understanding of the role of NO in brain function, which would potentially have many ramifications for more effective treatment of not only anxiety but other brain dysfunctions as well.
